Has Richard Mello received payments from drug or device companies?

Yes. Drug and device makers reported $1,426 in general payments to Richard Mello across 44 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Richard Mello did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Richard Mello come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Richard Mello

Family · Schertz, TXNPI 1801539622

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $769 and has fallen 83.8% since, to $125 in 2024.

$1,426in general payments, 2019–2025

Across 44 payments — averaging $32.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Amgen$235
GSK$137
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$128
AstraZeneca$125
Smith+Nephew$119
Bioventus LLC$110
plus $572 from 16 others

What the payments were for

Food & beverage$1,426100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Amgen(2 entities)	11	$235
GSK	2	$137
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	2	$128
AstraZeneca	1	$125
Smith+Nephew	1	$119
Bioventus LLC	3	$110
Argenx US, Inc.	1	$99
ERMI LLC	1	$83
Biohaven Pharmaceutical Holding Company Ltd.	3	$73
Merck	3	$48
AbbVie	2	$44
Shield Therapeutics Inc	2	$33
Lilly USA, LLC	2	$31
Novartis	2	$29
Kowa Pharmaceuticals America, Inc.	1	$22
Avanir Pharmaceuticals, Inc.	1	$19
Daiichi Sankyo Inc.	1	$19
Astellas Pharma US Inc	1	$18
Almatica Pharma LLC	1	$15
Corium, LLC	1	$14
Takeda Pharmaceuticals U.S.A., Inc.	1	$13
Novo Nordisk	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,426 in reported general payments places this provider in the 75th percentile of 15,456 family providers in Texas.

See all family providers in Texas →

Other family in Schertz

David WeirDallas$959K
Robin BeachHouston$428K
April LopezMcAllen$417K
Sarah AguilarHouston$199K
Sie ThomasDallas$197K
Anna CastroSan Antonio$184K
Jill CampbellShenandoah$182K
Angela AchaPflugerville$174K
Susan BowlinIrving$164K
Stephanie RodriguezCorpus Christi$159K

See the full list for Texas →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →